At the news
? NEUTRALIMPACT 5/10 8-K filed Aug 12, 2026 at 06:59 ET
Protalix reported Q2 2026 revenue of $19.9M, beating the $12.9M consensus, and EPS of $0.05, beating the $-0.01 consensus. Revenue growth was driven by higher Elfabrio sales to Chiesi and Fiocruz, partially offset by lower Pfizer purchases. The company reiterated full-year 2026 revenue guidance of $78M-$83M.
- Q2 2026 total revenue of $19.9M, up from $15.7M in Q2 2025
- Q2 2026 net income of $3.8M ($0.05 per share) vs net income of $164K ($0.00) in Q2 2025
- Revenues from selling goods were $19.8M in Q2 2026, up $4.4M from Q2 2025, driven by higher Elfabrio sales to Chiesi and Fiocruz
- Revenues from license and R&D services were $68K in Q2 2026 vs $218K in Q2 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access